drugset / Trial / NCT05858645
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Phase 4
Recruiting
25 enrolled
University of California, San Francisco
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelBasic science
Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2028-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRAVACITINIB | Small molecule | — | — |